MedTrace Logo

iLIVE Medication Study

NCT04717882 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2021-01-22

No results posted yet for this study

Summary

The iLIVE medication study is a before-after study where medication optimisation of patients with an estimated life expectancy of six months is investigated. The investigators will include 400 patients in 3 countries. The primary outcome is an assessment of the quality of life of patients, four weeks after baseline assessment

Conditions

  • Palliative Care

Interventions

DEVICE

CDSS-OPTIMED

The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient.

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • Landspitali University Hospital

    collaborator OTHER

  • Medical University of Vienna

    collaborator OTHER

  • Prof. dr. Stefan Sleijfer

    lead OTHER

Principal Investigators

  • Karin van der Rijt, PhD · Erasmus Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-15
Primary Completion
2023-01-15
Completion
2024-01-15

Countries

  • Netherlands
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04717882 on ClinicalTrials.gov